458 related articles for article (PubMed ID: 35620395)
21. RNA epigenetic modifications in ovarian cancer: The changes, chances, and challenges.
Ye L; Yao X; Xu B; Chen W; Lou H; Tong X; Fang S; Zou R; Hu Y; Wang Z; Xiang D; Lin Q; Feng S; Xue X; Guo G
Wiley Interdiscip Rev RNA; 2023; 14(5):e1784. PubMed ID: 36811232
[TBL] [Abstract][Full Text] [Related]
22. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
23. Epigenetics in ovarian cancer.
Natanzon Y; Goode EL; Cunningham JM
Semin Cancer Biol; 2018 Aug; 51():160-169. PubMed ID: 28782606
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
[TBL] [Abstract][Full Text] [Related]
25. C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.
Liu D; Zhang XX; Li MC; Cao CH; Wan DY; Xi BX; Tan JH; Wang J; Yang ZY; Feng XX; Ye F; Chen G; Wu P; Xi L; Wang H; Zhou JF; Feng ZH; Ma D; Gao QL
Nat Commun; 2018 Apr; 9(1):1739. PubMed ID: 29712898
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic programming contributes to development of drug resistance in hematological malignancies.
Wang QY; Zhong H
Front Biosci (Landmark Ed); 2015 Jan; 20(4):728-42. PubMed ID: 25553475
[TBL] [Abstract][Full Text] [Related]
27. Epigenetics in ovarian cancer.
Seeber LM; van Diest PJ
Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
[TBL] [Abstract][Full Text] [Related]
28. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.
Castilho RM; Squarize CH; Almeida LO
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704968
[TBL] [Abstract][Full Text] [Related]
30. microRNAs as biomarkers of ovarian cancer.
Zhang H; Lu B
Expert Rev Anticancer Ther; 2020 May; 20(5):373-385. PubMed ID: 32326768
[No Abstract] [Full Text] [Related]
31. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
[TBL] [Abstract][Full Text] [Related]
33. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
34. Emerging Epigenetic-Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment.
Zhang J; Huang L; Ge G; Hu K
Adv Sci (Weinh); 2023 Mar; 10(7):e2206169. PubMed ID: 36599655
[TBL] [Abstract][Full Text] [Related]
35. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
36. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
Xue B; Li S; Jin X; Liu L
BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
[TBL] [Abstract][Full Text] [Related]
37. Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.
Zhao L; Guo H; Chen X; Zhang W; He Q; Ding L; Yang B
Eur J Pharmacol; 2022 Jul; 927():175071. PubMed ID: 35636522
[TBL] [Abstract][Full Text] [Related]
38. Circular RNAs and their emerging roles as diagnostic and prognostic biomarkers in ovarian cancer.
Sheng R; Li X; Wang Z; Wang X
Cancer Lett; 2020 Mar; 473():139-147. PubMed ID: 31904484
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
